MediciNova (MNOV) News Today $1.61 +0.02 (+1.19%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV)StockNews.com initiated coverage on MediciNova in a research report on Thursday. They set a "hold" rating for the company.February 27, 2025 | marketbeat.comMediciNova's (MNOV) "Buy" Rating Reiterated at D. Boral CapitalFebruary 24, 2025 | americanbankingnews.comMediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $9.00 target price on shares of MediciNova in a report on Friday.February 22, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Issues Earnings ResultsMediciNova (NASDAQ:MNOV - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06).February 20, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets EstimatesMediciNova (NASDAQ:MNOV - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06).February 20, 2025 | marketbeat.comStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)StockNews.com began coverage on shares of MediciNova in a research note on Wednesday. They issued a "hold" rating for the company.February 19, 2025 | marketbeat.comMediciNova (MNOV) Projected to Post Quarterly Earnings on ThursdayMediciNova (NASDAQ:MNOV) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.comStockNews.com started coverage on MediciNova in a report on Monday. They set a "hold" rating for the company.February 3, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.comStockNews.com began coverage on MediciNova in a report on Sunday. They issued a "hold" rating on the stock.January 26, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Stock Price Passes Above 200-Day Moving Average - Here's WhyMediciNova (NASDAQ:MNOV) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?January 10, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average - Should You Sell?MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average - Should You Sell?January 10, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.comStockNews.com started coverage on MediciNova in a research report on Friday. They set a "hold" rating on the stock.January 10, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average - Time to Sell?MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average - Here's WhyJanuary 2, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on MediciNova in a research report on Thursday. They issued a "hold" rating for the company.January 2, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Share Price Passes Above 200-Day Moving Average - Should You Sell?MediciNova (NASDAQ:MNOV) Stock Price Passes Above 200-Day Moving Average - Should You Sell?December 17, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comStockNews.com began coverage on shares of MediciNova in a research note on Tuesday. They set a "hold" rating for the company.December 17, 2024 | marketbeat.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.comMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MNDDecember 5, 2024 | globenewswire.comMediciNova Inc.December 5, 2024 | wsj.comD. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy RecommendationDecember 3, 2024 | msn.comMediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finanznachrichten.deMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finance.yahoo.comMediciNova provides update in letter to stockholdersNovember 20, 2024 | markets.businessinsider.comMediciNova granted Notice of Allowance for MN-001 patent by USPTONovember 14, 2024 | markets.businessinsider.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the LiverNovember 14, 2024 | globenewswire.comMediciNova notified of settlement in Sanofi Novartis litigationNovember 12, 2024 | markets.businessinsider.comMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-NovartisNovember 11, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Shares Pass Above Two Hundred Day Moving Average - Here's WhyMediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving Average - Time to Sell?November 7, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?MediciNova (NASDAQ:MNOV) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?October 30, 2024 | marketbeat.comMediciNova announces update of Phase 2/3 MN-166 trial at NEALS meetingOctober 24, 2024 | markets.businessinsider.comMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)October 23, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.comStockNews.com began coverage on shares of MediciNova in a research note on Tuesday. They issued a "hold" rating on the stock.October 22, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comMediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years agoOctober 7, 2024 | finance.yahoo.comMNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…September 30, 2024 | msn.comShort Interest in MediciNova, Inc. (NASDAQ:MNOV) Increases By 19.3%MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 224,600 shares, an increase of 19.3% from the August 31st total of 188,200 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 39,300 shares, the days-to-cover ratio is presently 5.7 days.September 30, 2024 | marketbeat.comMediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)September 30, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Stock Price Crosses Above Two Hundred Day Moving Average of $1.42MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average of $1.42September 28, 2024 | marketbeat.comMediciNova, Inc. (NASDAQ:MNOV) Sees Large Increase in Short InterestMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 188,200 shares, an increase of 104.3% from the August 15th total of 92,100 shares. Approximately 0.4% of the company's stock are sold short. Based on an average daily trading volume, of 40,500 shares, the days-to-cover ratio is presently 4.6 days.September 15, 2024 | marketbeat.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MNDSeptember 9, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Stock Price Crosses Above 200-Day Moving Average of $1.36MediciNova (NASDAQ:MNOV) Share Price Passes Above 200-Day Moving Average of $1.36September 4, 2024 | marketbeat.comMediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) MeetingSeptember 3, 2024 | globenewswire.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID ConditionAugust 29, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth PlansAugust 28, 2024 | finance.yahoo.comMNOV Sep 2024 2.500 call (MNOV240920C00002500)August 20, 2024 | finance.yahoo.comMediciNova, Inc. (MNOV)July 26, 2024 | finance.yahoo.comMediciNova, Inc. (NASDAQ:MNOV) Short Interest UpdateMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 110,700 shares, a decline of 18.4% from the May 31st total of 135,600 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 34,200 shares, the days-to-cover ratio is presently 3.2 days.June 29, 2024 | marketbeat.comMediciNova Chief Business Officer David H. Crean, Ph.D.June 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid CancerJune 5, 2024 | globenewswire.comMediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024June 3, 2024 | globenewswire.com Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address MNOV Media Mentions By Week MNOV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNOV News Sentiment▼0.930.66▲Average Medical News Sentiment MNOV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNOV Articles This Week▼01▲MNOV Articles Average Week Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TKNO News Today ESPR News Today RGNX News Today PRME News Today BNTC News Today TERN News Today ATYR News Today IMMP News Today SLRN News Today SEPN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNOV) was last updated on 3/6/2025 by MarketBeat.com Staff From Our PartnersA crypto nightmareThis past weekend President Trump made good his promise to crypto enthusiasts - with his announcement of an of...Stansberry Research | SponsoredAlert: DOGE goes liveElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNOV Stock Alerts